###begin article-title 0
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">rd </sup>
###xml 133 137 <span type="species:ncbi:10116">rats</span>
Central neuropeptide Y receptors are involved in 3rd ventricular ghrelin induced alteration of colonic transit time in conscious fed rats
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Feeding related peptides have been shown to be additionally involved in the central autonomic control of gastrointestinal functions. Recent studies have shown that ghrelin, a stomach-derived orexigenic peptide, is involved in the autonomic regulation of GI function besides feeding behavior. Pharmacological evidence indicates that ghrelin effects on food intake are mediated by neuropeptide Y in the central nervous system.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 182 185 <span type="species:ncbi:10116">rat</span>
In the present study we examine the role of ghrelin in the central autonomic control of GI motility using intracerobroventricular and IP microinjections in a freely moving conscious rat model. Further the hypothesis that a functional relationship between NPY and ghrelin within the CNS exists was addressed.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 181 184 180 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 286 288 285 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 490 492 489 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
ICV injections of ghrelin (0.03 nmol, 0.3 nmol and 3.0 nmol/5 mul and saline controls) decreased the colonic transit time up to 43%. IP injections of ghrelin (0.3 nmol - 3.0 nmol kg-1 BW and saline controls) decreased colonic transit time dose related. Central administration of the NPY1 receptor antagonist, BIBP-3226, prior to centrally or peripherally administration of ghrelin antagonized the ghrelin induced stimulation of colonic transit. On the contrary ICV-pretreatment with the NPY2 receptor antagonist, BIIE-0246, failed to modulate the ghrelin induced stimulation of colonic motility.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 125 127 125 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
The results suggest that ghrelin acts in the central nervous system to modulate gastrointestinal motor function utilizing NPY1 receptor dependent mechanisms.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 658 659 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 743 744 743 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 974 975 974 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 976 977 976 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1388 1390 1388 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1391 1393 1391 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1747 1749 1747 1749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1818 1820 1818 1820 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1831 1832 1831 1832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1833 1835 1833 1835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1836 1838 1836 1838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 2026 2027 2026 2027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 2028 2030 2028 2030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 2082 2084 2082 2084 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 2090 2091 2090 2091 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 2141 2143 2141 2143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 2148 2150 2148 2150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 2366 2368 2366 2368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
The presence or absence of food in the gut stimulates the release of several regulatory peptides. These orexigenic (NPY, AGRP, ghrelin, MCH, Orexin-A, ...) and anorexigenic (CRF, CCK, CART, GLP-1, leptin, insulin, ...) peptides participating in the hypothalamic control of feeding behavior and satiety have been shown to be additionally involved in the autonomic control of gastointestinal (GI) functions like secretion and motility. For example fasted motor activity of the GI tract, e.g. the colon, is observed after intracerebroventricular (ICV) injection of neuropeptide Y whereas CRF ICV-treatment cause the disruption of fasted colonic motor activity [1]. Stomach-derived ghrelin is the first peripheral orexigenic peptide identified [2-6]. There is convincing evidence from several groups of investigators that ghrelin acts in the CNS and the periphery to simulate not only feeding but also GI function such as gastric acid secretion and gastric motility in rodents [7,9-11]. However, it is still unknown whether ghrelin is involved in the CNS control of other digestive functions besides gastric acid secretion and motility. Recent studies suggest that CNS-signaling by circulating ghrelin is mediated downstream by neurons of arcuate nucleus and the paraventricular nucleus of the hypothalamus, in particular, neurons expressing neuropeptide Y and agouti-related protein (AGRP) [12-14]. Furthermore it has been demonstrated that there is an anatomical interaction and functional relationship between ghrelin and neuropeptide Y. Using electrophysiological recordings Cowley et al have found that ghrelin stimulated the activity of arcuate NPYergic neurons and mimicked the effect of NPY in the paraventricular nucleus of the hypothalamus [15]. In addition ghrelin simulates food intake through hypothalamic NPY1 receptors [1,16,17]. Thus, the question came up "are NPY receptors involved in the ghrelin effect on GI function"? Among others, neuropeptide Y plays a role in the CNS control of gastrointestinal function [1,18]. NPY activates at least six receptor subtypes, NPY1 to NPY6. NPY binds preferentially with high affinity to Y1 and Y2 receptors, and there is evidence suggesting that these two receptor subtypes are involved in CNS regulation of digestive function by NPY action in arcuate nucleus and the paraventricular nucleus of the hypothalamus [18].
###end p 11
###begin p 12
Taken together there is overwhelming evidence that ghrelin, beside its satiety modulatory capacity, is involved in the CNS control of digestive function of the upper gastrointestinal tract. In the CNS ghrelin and NPY, the most potent orexigenic neuropeptides known, are anatomical associated and functionally related. Moreover hypothalamic NPYergic neurons are downstream mediators of feeding related ghrelin action.
###end p 12
###begin p 13
###xml 237 241 <span type="species:ncbi:10116">rats</span>
In the present study we scrutinize the hypothesis that central neuropeptide Y receptor activation is involved in the ghrelin induced modulation of gastrointestinal motility using a microinjection-model in conscious fed and freely moving rats.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Animals
###end title 15
###begin p 16
All experimental components described were performed in accordance with the requirements of German legislation for the protection of animals and were licensed and supervised by the appropriate government body.
###end p 16
###begin p 17
###xml 320 323 310 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 353 363 341 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ad libitum</italic>
###xml 5 24 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 302 305 <span type="species:ncbi:10116">rat</span>
###xml 392 396 <span type="species:ncbi:10116">rats</span>
Male Sprague-Dawley rats with a mean body weight of 350 +/- 50 g were maintained on a 12 : 12 h photoperiod. They were housed in colony cages under conditions of controlled humidity and temperature (22 +/- 2degreesC) for at least 7 days prior to the surgical procedure. The animals were fed a standard rat diet (Altromin(R), Lage, Germany) an tap water ad libitum. After surgical procedures, rats were housed individually. During experimental procedure the animals had continuous access to food and water.
###end p 17
###begin title 18
Drugs
###end title 18
###begin p 19
###xml 189 191 186 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 280 282 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 296 298 292 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 399 401 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 678 680 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 681 683 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1088 1090 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
Ghrelin (Bachem, Heidelberg, Germany) doses of 0.03 nmol (100 ng), 0.3 nmol (1 mug) and 3 nmol (10 mug)/5 mul were dissolved in 0.15 M sterile saline (B. Braun, Melsungen, Germany). The NPY1 receptor antagonist, BIBP-3226 (200 nmol/5 mul; Sigma-RBI, Natrick, MA, USA) [see Ref.: [19]] and the NPY2 receptor antagonist, BIIE-0246 (120 nmol/5 mul; Boehringer-Ingelheim, Biberach, Germany) [see Ref.: [21]] were dissolved in sterile 0.15 M saline. The NPY receptor antagonists were used in similar equipotent nanomolar concentrations. The used intracerebroventricular concentrations of the receptor antagonists were comparable with the ICV-dosages used by other groups in rodents [18,20]. Probes were aliquoted and frozen (-80degreesC). Fresh aliquots were thawed on each experimental day before injections. Any excess was discarded. In our hands nanomolar concentrations of BIBP-3226 and BIIE-0246 were effective in antagonization of NPY receptor subtypes without any side effects. In particular no central depressive effects or conspicuous behavior was observed after BIBP-3226 treatment [18].
###end p 19
###begin title 20
Cerebral cannulas
###end title 20
###begin p 21
###xml 84 87 84 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 146 149 146 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 25 29 <span type="species:ncbi:10116">rats</span>
For surgical procedures, rats were anesthetized with a mixture of ketamine (75 mg kg-1 i.p., Parke-Davis, Freiburg, Germany) and xylazine (5 mg kg-1 i.p., Bayer AG, Leverkusen, Germany). Animals were positioned in a stereotactic apparatus (David Kopf Instruments, Tujunga, CA). The head was fixed in a nose-down-position (-3 mm) and the skull exposed. Then trepanation of the skullcap was performed according to coordinates obtained from Paxinos and Watson [22] (mm from bregma: anterior-posterior = -3.30; lateral = +/- 0.0; dorsoventral = -3.8). According to these coordinates a 22-gauge guide cannula (Bilarney / Plastic one, Dusseldorf, Germany) was implanted into the third ventricle. The cannula was anchored by dental cement and stainless steel screws affixed to the skull. Dummy cannulas (28 G), extending 2 mm beyond the guide cannula tips, were inserted to prevent blockage. After cerebral surgery, animals were individually housed. The animals were allowed 4 days recovery after guide cannula surgeries before the abdominal surgical procedures were performed.
###end p 21
###begin title 22
Colonic catheter
###end title 22
###begin p 23
###xml 50 51 50 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 224 226 224 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 249 251 249 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 164 168 <span type="species:ncbi:10116">rats</span>
###xml 825 829 <span type="species:ncbi:10116">rats</span>
This method was performed as described elsewhere [1]. Prior to all abdominal surgeries, the animals were food deprived overnight. Four days after cerebral surgery, rats were anaesthetized with a mixture of ketamine (75 mg kg-1) and xylazine (5 mg kg-1). After laparatomy a polyethylene microcatheter (inside diameter, 1.2 mm; outside diameter 1.7 mm; Becton Dickinson, New Jersy, USA) was chronically implanted into the proximal colon 1 cm distal from the caecocolonic junction. The catheter was fixed at the colonic wall by a purse-string suture and routed subcutaneously to the interscapular region, where it was exteriorized through the skin and secured. The animals were allowed 7 days recovery after abdominal surgeries before the beginning of habituation training sessions. Experiments were performed in fed, conscious rats.
###end p 23
###begin title 24
Intraperitoneal (IP) and intracerebroventricular (ICV) microinjection
###end title 24
###begin p 25
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 376 378 376 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 440 442 440 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 565 568 <span type="species:ncbi:10116">rat</span>
###xml 594 597 <span type="species:ncbi:10116">rat</span>
The doses of ghrelin were calculated according to the lowest effective doses to stimulate food intake [see Ref.: [23]]. For IP injection a 1 ml syringe (Hamilton, Reno, NV, USA) was used. Ghrelin and vehicle were injected IP after central administration of vehicle or NPY receptor antagonist. For IP injections the low dose of ghrelin administered peripherally was 0.3 nmol kg-1/1 ml 0.15 M saline and the high dose of ghrelin was 3 nmol kg-1/1 ml saline. NPY receptor antagonists were injected ICV 15 min before ghrelin was given peripherally at doses of 200 nmol/rat (BIBP-3226) and 120 nmol/rat (BIIE-0246) respectively.
###end p 25
###begin p 26
###xml 946 950 <span type="species:ncbi:10116">rats</span>
For ICV injections a 1 mul micro syringe (Hamilton, Reno, NV, USA), attached to a 32 G injection needle via a PE-50 tube-catheter was used. The stainless steel injection cannulas (32 G) were cut to protrude 2 mm beyond the tips of the guide cannulas. The conscious animals were gently restrained by hand, the injection needle was inserted through the guide cannula, and vehicle (5 mul 0.15 M saline) or NPY receptor antagonists (BIBP-3226 200 nmol/5 mul; BIIE-0246 120 nmol/5 mul) and ghrelin (0.03 nmol, 0.3 nmol or 3 nmol/5 mul), were consecutively injected ICV slowly over a 60 s period. We used a 15 min time interval between ICV injection of receptor antagonist or vehicle and ICV ghrelin administration. The injection needle was left in place for 2 min after injection to allow diffusion of the solution and to prevent back flow. Then dummy cannulas were reinserted into the guide cannulas. After the last experimental testing session, the rats were anesthetized and 5 mul of alcian blue 8GX were injected ICV.
###end p 26
###begin title 27
Colonic transit time measurement
###end title 27
###begin p 28
Colonic transit time was calculated by using an enteral dye-marker. Trypan blue, a non-absorbable dye, was injected in 0.2 ml volume through the catheter positioned in the proximal colon and followed by a 0.2 ml saline flush immediately after the ICV or IP microinjection. Colonic transit time was evaluated as the time interval between dye injection and the discharge of the first blue pellet. Faecal pellet output was monitored continuously by a self-developed, automated observation system that mechanically registers the time of all bowel movements for 24 h. The device consists of a conveyor belt placed under the mesh bottom cage, which transports faecal pellets with defined velocity to a collector.
###end p 28
###begin title 29
Brain histology
###end title 29
###begin p 30
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 147 150 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 719 722 719 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">rd </sup>
###xml 99 103 <span type="species:ncbi:10116">rats</span>
The methods were performed as described in previous studies [17]. When experiments were completed, rats were anaesthetized with ketamine (75 mg kg -1 i.p.) and xylazine (5 mg kg -1 i.p.), and 0.05% alcian blue 8GX was microinjected intracerebroventricular under the same conditions as vehicle or peptide. The anaesthetized animals were transcardially perfused with phosphate buffered saline (PBS) buffer (0.1 M, pH 7.4) followed by Zamboni's fixative (2% formaldehyde and 2% picric acid in 0.1 M PBS buffer, pH 7.4). The brains were removed and cryoprotected in 25% sucrose. The site of injection was confirmed by inspection of intracerebroventricular dye distribution. Animals that received injections outside of the 3rd ventricle were excluded from data analysis.
###end p 30
###begin title 31
Experimental design
###end title 31
###begin title 32
Experiment I: Effect on colonic motorfunction of peripheral (IP) and central (ICV) ghrelin administration
###end title 32
###begin p 33
###xml 463 466 463 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 513 516 513 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 351 355 <span type="species:ncbi:10116">rats</span>
###xml 538 542 <span type="species:ncbi:10116">rats</span>
###xml 850 853 <span type="species:ncbi:10116">rat</span>
The aim of the first experiment was to determine whether exogenous ghrelin would alter colonic motor function. Thus in experiment I, dose response effects of ghrelin in the cerebrospinal fluid (ICV) and the periphery (IP) on colonic transit time were examined. Ghrelin or saline as a vehicle was administered ICV or IP in conscious lightly restrained rats as previously described. For IP injection the low dose of ghrelin administered peripherally was 0.3 nmol kg-1 BW and the high dose of ghrelin was 3.0 nmol kg-1 BW. After injections, rats were subsequently returned to their home cages and maintained in a non-stressful environment to monitor colonic transit time. In order to minimize interindividual variation, and to reduce the number of animals needed to perform this study, animals were tested twice in this study. In randomized order, each rat received vehicle and a single dose of ghrelin or vehicle ICV or IP. The time interval between the experiments performed on the same animal was at least 4 days.
###end p 33
###begin title 34
Experiment II: Effect of BIBP-3226 and BIIE-0246 pretreatment on centrally and peripherally injected ghrelin induced modulation of colonic transit
###end title 34
###begin p 35
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 209 210 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 231 233 231 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 464 466 464 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 472 474 472 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
In experiment II the hypothesis that ghrelin acts at the CNS to modulate colonic motor function via a NPY receptor dependent pathway was addressed. Therefore, we determined if a pretreatment with selective NPY1- (BIBP-3226) and NPY2 (BIIE-0246) receptor antagonists administered into the cerebrospinal fluid would block the alterations of colonic motor activity induced by centrally and peripherally administered ghrelin. The animals were pretreated with the NPY-Y1 and -Y2 receptor antagonists, injected ICV or vehicle (0.15 M saline), 15 min prior to ICV or IP ghrelin injections. Thereafter colonic transit time was assessed as described above.
###end p 35
###begin title 36
Data analysis
###end title 36
###begin p 37
The criterion used to include results in the data analysis of the ICV-injected group was the correct placement of the ICV cannulas.
###end p 37
###begin p 38
Results are expressed as mean +/- SEM. The data of all studies were analyzed by ANOVA and differences between groups were evaluated by the Student-Newmann-Keuls test. P < 0.05 was considered significant.
###end p 38
###begin title 39
Results
###end title 39
###begin title 40
Effect of peripherally (IP) and centrally (ICV) administered ghrelin on colonic motor function
###end title 40
###begin p 41
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 416 417 414 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 648 649 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 136 140 <span type="species:ncbi:10116">rats</span>
###xml 288 292 <span type="species:ncbi:10116">rats</span>
###xml 567 571 <span type="species:ncbi:10116">rats</span>
In experiment I, dose response effect of peripherally and centrally administered ghrelin on colon transit time in fed and freely moving rats were examined. As demonstrated in Fig. 1, ghrelin injected into the cerebrospinal fluid (CSF) stimulates colonic transit time dose dependently. In rats microinjected with vehicle into the CSF or IP, the average colonic transit time was 322 +/- 8 min. As demonstrated in Fig. 1, 0.03 nmol, 0.3 nmol and 3 nmol/5 mul ghrelin injected ICV dose-dependently decreased transit time by 24%, 34% and 43% respectively in conscious fed rats. Peripherally administered ghrelin accelerated transit time up to 36% (Fig. 1).
###end p 41
###begin title 42
###xml 55 58 55 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">rd </sup>
Effect of ICV NPY receptor antagonist pretreatment on 3rd ventricular and peripherally ghrelin induced stimulation of colonic transit
###end title 42
###begin p 43
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 212 214 212 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 539 542 539 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 583 585 583 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 624 625 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 663 665 663 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 777 778 777 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
The hypothesis that ghrelin acts in the brain to stimulate colonic transit via NPY receptor dependent mechanisms was addressed. As shown in Fig. 2, pre-treatment with BIBP-3226 (200 nmol) which is a selective NPY1 receptor antagonist 15 min prior to ICV application of 0.3 nmol ghrelin totally blocked the ghrelin induced effect on colonic transit. Application of BIBP-3226 into the CSF of the control group that was microinjected with vehicle, had no effect. Changes in colonic transit time induced by IP injection of ghrelin (3.0 nmol kg-1 BW) were canceled by ICV injection of NPY1 receptor antagonist, BIBP-3226. (Fig.: 2). Pretreatment with the selective NPY2 receptor antagonist, BIIE-0246, failed to affect the ghrelin induced alteration of colonic transit time. (Fig.: 2)
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 56 59 <span type="species:ncbi:10116">rat</span>
###xml 112 116 <span type="species:ncbi:10116">rats</span>
The present experiments using a freely moving conscious rat model permit the measurement of colonic motility in rats in the physiological fed status. The results demonstrated that ghrelin given ICV and IP stimulates gastrointestinal motility indicated by shortened colonic transit time. In addition we found that the NPY type 1 receptor is primarily involved in the ghrelin induced modulation of fasted motor activity of the colon.
###end p 45
###begin p 46
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 785 788 785 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1016 1018 1016 1018 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1029 1031 1029 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1032 1034 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1035 1037 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1203 1204 1203 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1427 1429 1427 1429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1435 1436 1435 1436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 1456 1457 1456 1457 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1466 1468 1466 1468 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1579 1581 1579 1581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1588 1590 1588 1590 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1666 1667 1666 1667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1668 1669 1668 1669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1670 1672 1670 1672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1719 1721 1719 1721 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1726 1728 1726 1728 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1837 1839 1837 1839 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1844 1846 1844 1846 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 2021 2023 2021 2023 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 2233 2235 2233 2235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 2420 2422 2420 2422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 2423 2425 2423 2425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 2629 2630 2629 2630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 2793 2794 2793 2794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 3403 3405 3403 3405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 3580 3582 3580 3582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 3843 3845 3843 3845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 3846 3848 3846 3848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 3908 3910 3908 3910 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 4008 4010 4008 4010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 4163 4165 4163 4165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 4333 4334 4333 4334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 4335 4337 4335 4337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 4595 4597 4595 4597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 4683 4687 4683 4687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 5004 5006 5004 5006 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 5045 5047 5045 5047 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 5094 5097 5094 5097 <sup xmlns:xlink="http://www.w3.org/1999/xlink">rd </sup>
###xml 5339 5341 5339 5341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 5356 5358 5356 5358 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 5427 5429 5427 5429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 5477 5479 5477 5479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 5512 5514 5512 5514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 5515 5517 5515 5517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 5557 5559 5557 5559 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 5563 5565 5563 5565 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 869 873 <span type="species:ncbi:10116">rats</span>
###xml 2550 2554 <span type="species:ncbi:10116">rats</span>
There is convincing evidence that the most effective appetite stimulating peptides, NPY and ghrelin, act in the CNS and the periphery to simulate not only feeding but also GI function such as gastric acid secretion and gastric motility [1,8-10]. Stomach derived ghrelin, first described in 1999 by Kojima et al., is the first peripheral orexigenic peptide identified [4]. Ghrelin was identified as endogenous ligand for the GH secretagogue receptor (GHS R) and a peripheral metabolic signal informing the brain about stomach nutrient load [17,24]. Physiological studies suggest a functional relationship of ghrelin and NPY within the brain. It has been demonstrated that peripherally (i.v.) and central (ICV) administered ghrelin increases the expression of the immediate early gene c-fos, a marker of neuronal activity, in the arcuate nucleus and the PVN in awake fed rats [25]. Furthermore, exogenous ghrelin increases mRNA levels for NPY into the arcuate nucleus and simulates food intake through hypothalamic NPY1 receptors [14,16,26]. Further Fujino et al. have demonstrated that ICV pretreatment with neuropeptide Y antiserum completely blocked ghrelin induced gastric and duodenal motoractivity [9]. Taken together these data suggest that there is an anatomical interaction and functional relationship between ghrelin and NPY within the brain. Six recognized subtypes of neuropeptide Y receptors have been described (NPY1 to NPY6). Two of these, NPY1- and NPY2 receptors, are found in high density in the hypothalamus. There is compelling evidence that, in particular, NPY1 and NPY2 receptors are involved in the CNS regulation of gastrointestinal function. [1,8,27] For this reason, we focused on neuropeptide Y1 and Y2 receptor pathways in the present study and did not investigate the role of neuropeptide Y receptor subtypes Y4 and Y5 which are also expressed in the hypothalamus and are also involved in the autonomic control of feeding behavior and GI function. In the present study pretreatment with the NPY1 receptor antagonist, BIBP-3226, blocked stimulation of colonic motility induced by systemic microinjection of exogenous ghrelin (ICV and IP). In our hands BIIE-2046, which is a selective antagonist of the NPY Y2 receptor, failed to affect the ghrelin induced induction of fasted motor activity. It was previously described that knocking out NPY significantly decreases ghrelin stimulated feeding [17,28]. In this context Fujino et al. have recently demonstrated that the ghrelin induced fasted gastroduodenal motor activity in rats is blocked by ICV injection of GHS-R antagonist as well as NPY antiserum [9]. The results presented by Fujino et al. also suggest that the vagal pathway may mediate the action of centrally administered ghrelin on gastroduodenal motility [9]. Thus we can speculate that central NPY pathways, e.g. centrally NPY receptor activation, are the primary downstream mediator of circulating ghrelin. This interpretation is consistent with neuroanatomical and physiological facts: Neuropeptide Y works at two sites, locally within the arcuate nucleus to inhibit POMC neuronal activity and at afferent-terminal sites, in particular the paraventricular nucleus of the hypothalamus. Guan et al. have shown that neuropeptide Y- and ghrelin like immunoreactive (LI) neurons within the arcuate nucleus could influence each other by complex synaptic transmissions [29]. Furthermore Cowley et al. have demonstrated that ghrelin stimulated the activity of arcuate neuropeptide Y-LI neurons and mimicked the effect of neuropeptide Y in the PVN [15]. Compelling evidence showed that NPY projections from the arcuate nucleus (ARC) to the PVN are involved in the CNS regulation of food intake and other physiological functions of the organism, e.g. digestive function, by neuroendocrine and autonomic pathways [17,18]. For example NPY released from ARC neurons activates NPY-Y1 receptors in the hypothalamus, e.g. the PVN, and results in the stimulation of GI motor function [18]. Furthermore arcuate NPYergic neurons have been thought to regulate feeding behavior by NPY receptor subtypes Y1 and Y5 in the PVN and adjacent areas [17]. Pretreatment with a Y1, but not other receptor antagonist markedly inhibited ghrelin-induced feeding, pointing to NPY receptor Y1 as one of the downstream pathways [9,17]. With regard to the characteristic physiological feature that peripheral ghrelin does not cross the blood-brain barrier in rodents it is important to note that the arcuate nucleus is the only hypothalamic structure located outside the brain-blood barrier [30]. Thus we can speculate that circulating ghrelin modulates gastrointestinal motility via activation of hypothalamic, in particular by using NPYergic pathways via activation of NPY-Y1 receptors, in the arcuate nucleus. This hypothesis is in good agreement with our observation that the effect of peripherally (IP) administered ghrelin on colonic motility is blocked by ICV pretreatment with the specific NPY1 receptor antagonist, BIBP-3226. The NPY2 receptor antagonist BIIE-0246 injected in the 3rd ventricle at the equipotent dose as BIBP-3226 was not effective to antagonize the ghrelin effect on GI motility significantly. This data suggests that ghrelin unfolds a stimulatory effect on colonic motility primarily by acting on central NPY1 and not via NPY2 receptors. This interpretation is confirmed by the observation that Y1 receptors acts rather postsynaptically and the Y2 receptor rather presynaptically [31,32] The question of whether neuropeptide Y4 or Y5 receptors in the CNS are involved in the CNS control of gastrointestinal function should be examined in future studies.
###end p 46
###begin title 47
Conclusion
###end title 47
###begin p 48
###xml 559 562 559 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">rd </sup>
###xml 657 660 657 660 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
We hypothesize that circulating ghrelin exhibits its effect by activating hypthalamic neurons, in particular neurons in the arcuate nucleus bearing GHS- and NPY-Y1 receptors. Further this ghrelin induced neuronal activation leads to stimulation of GI motor function by activation of higher hypothalamic brain sites, e.g. activation of neuronal projections within the paraventricular nucleus of the hypothalamus. On the other hand it is possible that the site of action of circulating ghrelin is not the hypothalamus but other brain sites. In our model using 3rd ventricular injection of ghrelin this could simply mean that the peptide gained access to the 4th ventricle and reached further caudal brain sites, e.g. NTS, DVC and medulla oblongata. With respect to the distribution of GHS- and NPY receptors in the CNS this hypothesis is possible, but how ghrelin action on any of these brain sites would modulate digestive function is not known. This question should be examined in future studies
###end p 48
###begin p 49
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
In summary, we presented evidence that ghrelin is involved in the CNS control of GI function. Apart from humoral pathways ghrelin acts into the CNS to control GI function by a mechanism of action involving neuropeptide Y1 receptor pathways. Further this study support the hypothesis giving by Chen et al. that ghrelin has an absolute requirement for neuropeptide Y pathways to unfold its physiological effects [28].
###end p 49
###begin title 50
List of abbreviations
###end title 50
###begin p 51
AGRP agouti-related peptide
###end p 51
###begin p 52
ARC arcuate nucleus
###end p 52
###begin p 53
CART cocain- and amphetamine-regulated transcript
###end p 53
###begin p 54
CCK cholecystokinin
###end p 54
###begin p 55
CNS central nervous system
###end p 55
###begin p 56
CSF cerebrospinal fluid
###end p 56
###begin p 57
CRF corticotropin releasing factor
###end p 57
###begin p 58
DVC dorsal motor nucleus of vagus
###end p 58
###begin p 59
GHS-R growth hormone secretagogue receptor
###end p 59
###begin p 60
GLP-1 glucagon like peptide-1
###end p 60
###begin p 61
ICV intracerebroventricular
###end p 61
###begin p 62
MCH melanocortin hormone
###end p 62
###begin p 63
MI microinjection
###end p 63
###begin p 64
NPY neuropeptide Y
###end p 64
###begin p 65
NTS nucleus of the solitary tract
###end p 65
###begin p 66
POMC proopiomelanocortin
###end p 66
###begin p 67
PVN paraventricular nucleus of the hypothalamus
###end p 67
###begin title 68
Competing interests
###end title 68
###begin p 69
The author(s) declare that they have no competing interests.
###end p 69
###begin title 70
Authors' contributions
###end title 70
###begin p 71
JJT participated in the design and coordination of the study, performed the microinjection studies and drafted the manuscript. CGT was the surgeon in charge and participated in the animal experiments. M-KHS and SM were involved in the design and coordination of the study. MR participated in the analysis and interpretation of data and revised the manuscript critically.
###end p 71
###begin title 72
Pre-publication history
###end title 72
###begin p 73
The pre-publication history for this paper can be accessed here:
###end p 73
###begin p 74

###end p 74
###begin title 75
Acknowledgements
###end title 75
###begin p 76
We are grateful to Boehringer-Ingelheim, Biberach, Germany, for the generous donation of BIIE-0246. This work was supported by a grant from the German Research Foundation (DFG) to J.J.T. and M. K.-H. S. (DFG: TE 307 1-2). Part of this study contained in the medical thesis of CG Tebbe. We thank R. Weber for excellent technical support.
###end p 76
###begin article-title 77
Neuropeptide Y in the paraventricular nucleus of the hypothalamus stimulates colonic transit by peripheral cholinergic and central CRF pathways
###end article-title 77
###begin article-title 78
Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin
###end article-title 78
###begin article-title 79
###xml 141 145 <span type="species:ncbi:10116">rats</span>
###xml 150 156 <span type="species:ncbi:9606">humans</span>
Ghrelin a novel growth hormone releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tract of rats and humans
###end article-title 79
###begin article-title 80
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
###end article-title 80
###begin article-title 81
A role for ghrelin in the central regulation of feeding
###end article-title 81
###begin article-title 82
###xml 79 82 <span type="species:ncbi:9615">dog</span>
Identification of cDNA encoding motilin-related-peptide/ghrelin precursor from dog fundus
###end article-title 82
###begin article-title 83
Ghrelin acts in the central nervous system to stimulate gastric acid secretion
###end article-title 83
###begin article-title 84
###xml 93 97 <span type="species:ncbi:10116">rats</span>
Neuropeptide Y induces fasted pattern of duodenal motility via Y2 receptors in conscious fed rats
###end article-title 84
###begin article-title 85
###xml 85 89 <span type="species:ncbi:10116">rats</span>
Ghrelin induces fasted motor activity of the gastrointestinal tract in conscious fed rats
###end article-title 85
###begin article-title 86
###xml 58 62 <span type="species:ncbi:10116">rats</span>
Ghrelin stimulates gastric acid secretion and motility in rats
###end article-title 86
###begin article-title 87
###xml 97 100 <span type="species:ncbi:10116">rat</span>
Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat
###end article-title 87
###begin article-title 88
###xml 4 7 <span type="species:ncbi:10116">rat</span>
The rat arcuate nucleus integrates peripheral signals provided by leptin, insulin and a ghrelin mimetic
###end article-title 88
###begin article-title 89
###xml 132 136 <span type="species:ncbi:10116">rats</span>
Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and aguoti-related protein mRNA levels and body weight in rats
###end article-title 89
###begin article-title 90
###xml 114 117 <span type="species:ncbi:10116">rat</span>
Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus
###end article-title 90
###begin article-title 91
The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis
###end article-title 91
###begin article-title 92
Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway
###end article-title 92
###begin article-title 93
Ghrelin: An orexigenic and somatotrophic signal from the stomac
###end article-title 93
###begin article-title 94
###xml 26 29 <span type="species:ncbi:10116">rat</span>
Stimulation of neurons in rat ARC inhibits gastric acid secretion via hypothalamic CRF 1/2- and NPY-Y1 receptors
###end article-title 94
###begin article-title 95
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226
###end article-title 95
###begin article-title 96
###xml 102 107 <span type="species:ncbi:10090">mouse</span>
The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test
###end article-title 96
###begin article-title 97
BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist
###end article-title 97
###begin article-title 98
###xml 4 7 <span type="species:ncbi:10116">rat</span>
The rat brain in stereotaxic coordinates
###end article-title 98
###begin article-title 99
Hypothalamic paraventricular injections of ghrelin: effect on feeding and c-Fos immunoreactivity
###end article-title 99
###begin article-title 100
Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a
###end article-title 100
###begin article-title 101
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
Peripheral ghrelin selectively increases Fos expression in neuropeptide Y-synthesizing neurons in mouse hypothalamic arcuate nucleus
###end article-title 101
###begin article-title 102
###xml 99 102 <span type="species:ncbi:10116">rat</span>
Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat
###end article-title 102
###begin article-title 103
###xml 69 73 <span type="species:ncbi:10116">rats</span>
Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats
###end article-title 103
###begin article-title 104
Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein
###end article-title 104
###begin article-title 105
###xml 84 87 <span type="species:ncbi:10116">rat</span>
Synaptic interactions between ghrelin- and neuropeptide Y-containing neurons in the rat arcuate nucleus
###end article-title 105
###begin article-title 106
Extent and direction of ghrelin transport across the blood-brain barriers is determined by its unique primary structure
###end article-title 106
###begin article-title 107
###xml 44 47 <span type="species:ncbi:10116">rat</span>
Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor
###end article-title 107
###begin article-title 108
Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides
###end article-title 108
###begin title 109
Figures and Tables
###end title 109
###begin p 110
###xml 37 40 37 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">rd </sup>
###xml 317 319 315 317 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 361 363 358 360 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B </bold>
###xml 404 406 400 402 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C </bold>
###xml 445 447 440 442 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D </bold>
###xml 468 471 463 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 475 477 470 472 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E </bold>
###xml 498 501 493 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
Effect of ghrelin injected into the 3rd ventricle (ICV) and intraperitoneally (IP) on colonic transit time. Ghrelin injected ICV as well as IP induced a dosed-related stimulation of propulsive colonic motor activity. MI = microinjection The bars represent the mean +/- SEM. * P < 0.05 vs. vehicle. â–  = vehicle-group; A = 0.03 nmol ghrelin /5 mul 0.15 M saline; B = 0.3 nmol ghrelin /5 mul 0.15 M saline; C = 3 nmol ghrelin /5 mul 0.15 M saline; D = 0.3 nmol ghrelin kg-1 BW; E = 3.0 nmol ghrelin kg-1 BW
###end p 110
###begin p 111
###xml 199 201 199 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 345 347 345 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Effect of pretreatment with NPY receptor antagonists on fasted motor activity of the colon induced by centrally (ICV) and peripherally (IP) administered ghrelin. BIBP-3226, which is a selective NPY Y1 receptor antagonist, injected ICV antagonizes the stimulation of colonic transit induced by ghrelin injected in the same route and IP. The NPY Y2 receptor antagonist BIIE-2046 injected ICV fails to affect the stimulated colonic motoractivity induced by ICV or IP injection of ghrelin. MI = microinjection The bars represent the mean +/- SEM. * P < 0.05 vs. vehicle-group; #P < 0.05 vs. ghrelin-group
###end p 111

